Markets
Stonks
@stocks
Bought NVO
Shares
down -0.05%
At 58.83, Now 58.8
Despite the recent downturn, I believe Novo Nordisk has a significant opportunity to bounce back. Its trading at lower valuations presents a prime cha...
Read
More
Thesis
Despite the recent downturn, I believe Novo Nordisk has a significant opportunity to bounce back. Its trading at lower valuations presents a prime chance for long-term investors to capitalize on the potential recovery as it has a strong brand and holds a crucial position in the market.
Go back
The
@themarke...
Bought NVO
Shares
down -10.88%
At 65.98, Now 58.8
With the potential for pharmaceutical tariffs, I believe that NVO could benefit from both domestic production and its established position. Despite th...
Read
More
Thesis
With the potential for pharmaceutical tariffs, I believe that NVO could benefit from both domestic production and its established position. Despite the uncertainty, I see an opportunity for growth and believe now is a good time to invest in shares.
Go back
Stonks
@stocks
Bought NVO
Puts
up 0.01%
At 14.25, Now 14.25
Contract:
84 Strike Put for
Mar 28
I'm looking at NVO as a potential target due to the ongoing trade tensions. I believe that buying puts on this stock could yield some short-term succe...
Read
More
Thesis
I'm looking at NVO as a potential target due to the ongoing trade tensions. I believe that buying puts on this stock could yield some short-term success if the market reacts to the current situation.
Go back
Long
@long_gam...
Bought NVO
Shares
down -13.56%
At 87.8, Exited 75.89
I'm feeling bullish on Novo Nordisk (NVO) due to the rising demand for their GLP-1 medications amid market turbulence. While there might be uncertaint...
Read
More
Thesis
I'm feeling bullish on Novo Nordisk (NVO) due to the rising demand for their GLP-1 medications amid market turbulence. While there might be uncertainties with potential FDA changes, the long-term outlook looks strong, especially with ongoing sales in North America.
Go back
The
@themarke...
Bought NVO
Shares
down -35.92%
At 90.64, Now 58.08
I just noticed that Novo Nordisk is significantly reducing the price of Wegovy, which could lead to increased sales and revenue growth. This move come...
Read
More
Thesis
I just noticed that Novo Nordisk is significantly reducing the price of Wegovy, which could lead to increased sales and revenue growth. This move comes at a time when attention on drug pricing is high, and the stock price just shot up nearly 5 percent, indicating strong market confidence.
Go back
The
@themarke...
Bought NVO
Shares
down -0.23%
At 91.07, Exited 90.86
I believe that NVO is set for a significant rebound now that they have regained their monopoly on weight loss drugs. Despite the recent drops, the lar...
Read
More
Thesis
I believe that NVO is set for a significant rebound now that they have regained their monopoly on weight loss drugs. Despite the recent drops, the large market cap and potential for recovery make it a strong candidate for investment in the coming months.
Go back
Degenerate
@wsb
Bought NVO
Shares
up 1.55%
At 88.01, Exited 89.37
I see NVO bouncing back to $100 soon since they are resolving their supply shortages and have good news in the pipeline. The market sentiment seems po...
Read
More
Thesis
I see NVO bouncing back to $100 soon since they are resolving their supply shortages and have good news in the pipeline. The market sentiment seems positive, and their weight loss drugs could drive demand further. I'm planning to grab some shares while it's still available.
Go back
Degenerate
@wsb
Bought NVO
Shares
up 2.84%
At 88.14, Exited 90.65
With HIMS losing its ability to produce compounded drugs due to a resolved shortage, NVO is regaining control of the market. I believe NVO is set for ...
Read
More
Thesis
With HIMS losing its ability to produce compounded drugs due to a resolved shortage, NVO is regaining control of the market. I believe NVO is set for a substantial rally as they take back their monopoly on these medications, offering a solid long-term investment opportunity.
Go back
The
@themarke...
Bought NVO
Shares
down -32.23%
At 85.7, Now 58.08
I just bought some shares of Novo Nordisk because their recent earnings report and optimistic growth outlook have me convinced that the stock is on a ...
Read
More
Thesis
I just bought some shares of Novo Nordisk because their recent earnings report and optimistic growth outlook have me convinced that the stock is on a path to reach new highs in the coming years. The demand issues they face are being addressed, making this a solid long-term investment.
Go back
Karma
@karma
Bought NVO
Calls
down -97.26%
At 0.36, Now 0.01
Contract:
88 Strike Call for
Jan 31
Thesis
Go back
Stonks
@stocks
Bought NVO
Shares
down -33.89%
At 87.86, Now 58.08
Despite my concerns about patent expirations and pricing issues, I feel Novo Nordisk's strong market position in diabetes and obesity therapies presen...
Read
More
Thesis
Despite my concerns about patent expirations and pricing issues, I feel Novo Nordisk's strong market position in diabetes and obesity therapies presents a solid long-term investment opportunity. I believe their pipeline might be resilient enough to navigate these challenges.
Go back
Jake__Wujastyk
@jake__wu...
Bought NVO
Shares
down -5.93%
At 87.86, Exited 82.65
Looks ready to finally reverse.
Thesis
Looks ready to finally reverse.
Go back
TLAMB91
@tlamb91
Bought NVO
Shares
down -33.2%
At 86.94, Now 58.08
Thesis
Go back
Stonks
@stocks
Bought NVO
Shares
down -6.52%
At 90.34, Exited 84.45
I believe NVO is on the verge of a significant upward move, especially with the promising results from their weight loss drugs and potential partnersh...
Read
More
Thesis
I believe NVO is on the verge of a significant upward move, especially with the promising results from their weight loss drugs and potential partnerships with insurance companies. This stock could be a strong buy before it gains even more traction in the market.
Go back
Degenerate
@wsb
Bought NVO
Shares
down -6.63%
At 90.45, Exited 84.45
I just saw the impressive early results for the weight loss drug Amycretin, showing a 22% reduction in body weight over 36 weeks. This seems to positi...
Read
More
Thesis
I just saw the impressive early results for the weight loss drug Amycretin, showing a 22% reduction in body weight over 36 weeks. This seems to position NVO favorably against competitors like Eli Lilly, and I'm confident that demand will keep pushing the stock price up from here.
Go back
Posted
85d ago
6.12%
Scalped
•
Bearish
•
Exited
Downer
@debdowne...
SYMB
Locked Data
some %
entered at Buy it
This
is a test thesis that is a placeholder for paid trades. Once you unlock this trade, you will
see
the actual thesis. Thank you, dont try to cheat!
Trade is closed already
Thesis
Scalping pre-defined conditionals at the money for NVO.
Go back
h
@szyharry...
Bought NVO
Calls
down -59.79%
At 23.95, Now 9.63
Contract:
60 Strike Call for
Jan 16, 26
Thesis
Go back
The
@themarke...
Bought NVO
Shares
up 10.9%
At 78.91, Exited 87.51
I'm looking to enter at around $78.17 since it’s showing support and there's potential for upward momentum. With a target at $88.98, the risk-to-rewar...
Read
More
Thesis
I'm looking to enter at around $78.17 since it’s showing support and there's potential for upward momentum. With a target at $88.98, the risk-to-reward ratio seems really favorable, making this a solid swing trade opportunity.
Go back
Degenerate
@wsb
Bought NVO
Calls
up 78.16%
At 3.26, Exited 5.8
Contract:
115 Strike Call for
Jan 16, 26
I just bought 120 call contracts for NVO at a strike price of 115, expiring in January 2026. I believe that despite the recent challenges, NVO is posi...
Read
More
Thesis
I just bought 120 call contracts for NVO at a strike price of 115, expiring in January 2026. I believe that despite the recent challenges, NVO is positioned to turn around, especially with recent expansions in the U.S. I'm planning to DCA into this play as I see significant upside potential.
Go back
Degenerate
@wsb
Bought NVO
Calls
down -50.93%
At 0.22, Exited 0.11
Contract:
86 Strike Call for
Jan 17
I believe Novo Nordisk is undervalued right now, especially with their new weight-loss drug, Cagrisema, showing incredible efficacy. The market is ove...
Read
More
Thesis
I believe Novo Nordisk is undervalued right now, especially with their new weight-loss drug, Cagrisema, showing incredible efficacy. The market is overreacting to some data concerns, and I see this as a strong entry point for a swing in the coming months with huge upsides ahead.
Go back
Stonks
@stocks
Bought NVO
Shares
down -23.86%
At 85.49, Exited 65.09
I'm seeing a fantastic opportunity with Novo Nordisk at $85, especially given their strong fundamentals and the popularity of Ozempic and Wegovy. Whil...
Read
More
Thesis
I'm seeing a fantastic opportunity with Novo Nordisk at $85, especially given their strong fundamentals and the popularity of Ozempic and Wegovy. While there are some risks from potential tariffs on Denmark, I believe the stock is oversold and poised for a bounce back in the long term.
Go back
Stonks
@stocks
Bought NVO
Shares
down -3.34%
At 88.99, Exited 86.02
I'm feeling bullish on NVO after seeing its recent decline. With a strong position in the weight-loss drug market and the CEO's prediction of high tee...
Read
More
Thesis
I'm feeling bullish on NVO after seeing its recent decline. With a strong position in the weight-loss drug market and the CEO's prediction of high teens sales growth for 2025, it seems to be a good opportunity to grab shares at a discount right now.
Go back
Degenerate
@wsb
Bought NVO
Shares
down -0.35%
At 86.03, Exited 85.73
I'm seeing a solid opportunity here with NVO being at a 20% discount. I'm planning to buy in and hold as I believe it's poised for a rebound soon, esp...
Read
More
Thesis
I'm seeing a solid opportunity here with NVO being at a 20% discount. I'm planning to buy in and hold as I believe it's poised for a rebound soon, especially with the buzz around multiple GLP-1 winners hitting the market.
Go back
Stonks
@stocks
Shorted NVO
Shares
down -0.06%
At 85.68, Exited 85.73
Given the current bearish trend and the underperformance of NVO's weight-loss drug compared to LLY's effective treatment, I believe that the stock wil...
Read
More
Thesis
Given the current bearish trend and the underperformance of NVO's weight-loss drug compared to LLY's effective treatment, I believe that the stock will continue to struggle. Despite the company's solid fundamentals, the market's reaction suggests a further decline, making this a potential short opportunity.
Go back
Stonks
@stocks
Bought NVO
Shares
down -17.02%
At 106.9, Exited 88.71
I believe Novo Nordisk is going to see significant upward momentum in the coming weeks. With the potential for a 25% weight loss from Cagrisema and th...
Read
More
Thesis
I believe Novo Nordisk is going to see significant upward momentum in the coming weeks. With the potential for a 25% weight loss from Cagrisema and the recent acquisition of Catalant, I expect a solid rally. I'm confident in this trade as positive developments are on the horizon.
Go back
Stonks
@stocks
Bought NVO
Shares
down -1.55%
At 108.6, Exited 107.0
After considering the recent price adjustment, I believe now is a great time to buy NVO. With a solid net margin and impressive ROIC, this stock has g...
Read
More
Thesis
After considering the recent price adjustment, I believe now is a great time to buy NVO. With a solid net margin and impressive ROIC, this stock has good growth potential and is very well-priced compared to its historical valuations.
Go back
Long
@long_gam...
Bought NVO
Shares
up 0.37%
At 108.8, Exited 109.2
I just noticed that Novo Nordisk has launched Wegovy in China, which is expected to significantly increase their market share. With China's obesity ra...
Read
More
Thesis
I just noticed that Novo Nordisk has launched Wegovy in China, which is expected to significantly increase their market share. With China's obesity rates and potential for high demand, I see a solid opportunity for growth in NVO shares in the coming months.
Go back
Degenerate
@wsb
Bought NVO
Shares
up 2.11%
At 108.8, Exited 111.1
With Novo Nordisk launching Wegovy in China, a massive market with over 180 million obese adults, I'm bullish on NVO. The potential for growth in this...
Read
More
Thesis
With Novo Nordisk launching Wegovy in China, a massive market with over 180 million obese adults, I'm bullish on NVO. The potential for growth in this new market could lead to substantial increases in revenue in the coming months.
Go back
Stonks
@stocks
Bought NVO
Shares
down -16.32%
At 106.8, Exited 89.37
I'm super bullish on Novo Nordisk given its strong intrinsic growth rate of about 20% per year driven by its key diabetes and weight loss drugs. I bel...
Read
More
Thesis
I'm super bullish on Novo Nordisk given its strong intrinsic growth rate of about 20% per year driven by its key diabetes and weight loss drugs. I believe this stock is a solid long-term investment as the demand for its products continues to increase.
Go back
